NICE International, London, UK.
Clin Pharmacol Ther. 2010 Mar;87(3):264-6. doi: 10.1038/clpt.2009.243.
Public and private payers in rich and emerging economies are becoming increasingly interested in using evidence to inform health-care resource allocation decisions. The National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has been doing so on behalf of the National Health Service (NHS) for more than 10 years. To some, NICE-type entities are barriers to access and innovation. Increasingly, however, even NICE's critics appreciate that evidence-informed decision making, carried out in a fair, inclusive, and transparent way, is better than arbitrary government-imposed price cuts. For health-care systems in developed and developing countries around the world, faced with limited budgets, there may be no third option.
在富裕和新兴经济体中，公共和私人支付方越来越有兴趣利用证据来为医疗资源分配决策提供信息。英国国家卫生与临床优化研究所（NICE）已经代表国民保健制度（NHS）这样做了 10 多年。对一些人来说，NICE 类型的实体是获取和创新的障碍。然而，越来越多的人甚至包括 NICE 的批评者都认识到，以公平、包容和透明的方式进行基于证据的决策，要好于政府任意强加的降价。对于面临有限预算的全球发达国家和发展中国家的医疗体系来说，可能别无选择。
